Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific share transaction:
- Share Purchase Price: 1486.9353 pence per share.
- Transaction Date: July 6, 2012.
- Shares Acquired: 134 Ordinary Shares.
Material Changes
The filing details an increase in the holding of Ordinary Shares by Dr. S. Dexter, a connected person of Director Dr. P. J. T. Vallance. This increase resulted from the re-investment of the dividend paid to shareholders on July 5, 2012, and the subsequent purchase of shares on July 6, 2012. No material changes to the company's overall financial position are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a connected person's share transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Verify the total shareholding of Dr. S. Dexter post-transaction to assess concentration of ownership.
- Confirm the dividend reinvestment plan terms applicable to the July 5, 2012 dividend.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financials.